Our Vision & Experience
Millions of people suffer every year from inadequate outcomes and severe side effects of prescription medications that were meant to help them. Our discoveries have the potential to change and improve lives.
Founders, Dr. Brian D. Athey and Dr. James S. Burns
For decades, researchers have pursued coding-gene pharmacogenomic testing as a way of improving medication selection and reducing medication side effects. Despite advances, the results have been limited in their ability to predict patient outcomes, interpret drug-drug interactions, and avoid potential adverse reactions.
The Breakthrough
A University of Michigan team, led by Dr. Brian D. Athey, developed a breakthrough technology for determining how individual genes are impacted by specific drugs, when evaluated in a combination with external environmental factors and patient traits, such as network biology, ethnicity, environment, sociological factors, and recorded health history.
The result is a highly predictive profile of a patient’s unique drug response or phenotype. Athey and biotechnology entrepreneur Dr. James S. Burns evaluated the potential applications of advanced pharmacogenomics and created a plan to move the technology forward. Phenomics Health Inc. (PHI) was launched in 2018 and PHI’s proprietary Precision Phenome Platform™ (P3) was introduced.
Precision
Dedicated to commercializing novel pharmacogenomic and precision medicine products and services across therapeutic areas associated with chronic pain, mental illness, stress, and cardiovascular disease.
Research
Phenomics Health provides contract-based and collaborative research services to test mechanisms and pathways for new and repurposed drugs, including CNS, cardiovascular disease, cancer, GI, and immune system disorders.
Technology
Patented pharmacogenomic technology, enabled by Artificial Intelligence (AI) and Machine Learning, fuels the precision of Phenomics Health technological breakthroughs.
Phenomics Health’s technology is based on University of Michigan inventions, licensed exclusively to Phenomics Health. The company has two issued and multiple pending patents.
Proprietary Intellectual Property and multiple products in development
Proprietary Phenome Analytics Support Platform
Multiple publications supporting its core technology and specific applications
Multiple pending collaborations and partnerships with key U.S. and international institutions
International and external informatics with hosted secure cloud server support
Access to multiple proprietary informatics and multiple technologies and data sets
Our Team
James S Burns
Founding Partner
Chairman & CEO
Brian D. Athey
Founding Partner
Chief Science & Tech Officer
Pamela Weir
Board Director
Gilbert S. Omenn
Director and Chair,
Scientific Advisory Board (SAB)
Alex Ade
Principal Software Architect
Michaela Gallucci
Software Engineer
Gerry Higgins
Senior PGx Scientist
Wenbing Chen
Laboratory Director
Madison Censoni
Associate Lab Manager
Guy Giordano
Laboratory
Rajvi Patel
Laboratory Technologist
Cassandra Snyder
Laboratory Technologist
Dylan Kakos
Medical Science Liaison
Eric Bell
Director of Sales
Our Scientific Advisors
Nicholas J. Schork, Ph.D.
Distinguished Professor and Director of Quantitative Medicine at The Translational Genomics Research Institute (TGen)
Veera Baladandayuthupani, Ph.D.
Professor of Biostatistics, University of Michigan
Ryan B. Morrison, B.Sc.
Director of Operations, Protypia Laboratory Innovator of Quantitative PK/PD Assays, Specializing in High Throughput Drug Metabolism Assays
Join the conversation.
Keep up with our latest news and innovation by following us on LinkedIn.